Hemoglobin Kinetics in Response to Mircera® in Patients With Acute Myocardial Infarction

• Status: Completed
• Trial end date: 2010-10-01
• Target enrollment: 0
• Participant gender: All

Summary

Hypothesis:

Based on available pharmacokinetic data from healthy volunteers we hypothesize that the administration of a cumulative dose of 210μg of the continuous erythropoietin receptor activator, Mircera® (Roche), during 3 months post percutaneous coronary intervention (PCI) does not result in hemoglobin (Hb) levels >15 g/dl in patients with ST-segment elevation myocardial infarction (STEMI)

Design:

Prospective, open label single center pilot study

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: University Hospital, Basel, Switzerland
• Treatments: Epoetin Alfa

Criteria

Inclusion Criteria:

• Patients (age 18 - 80 years) with acute STEMI undergoing PCI

Main Exclusion Criteria:

• Hemoglobin levels >15g/dL

• history of a myeloproliferative syndrome

• thrombolysis for index infarction

• anticipated additional revascularization within 3 months

• cardiogenic shock